Drug
Nifurtimox clinical trials
Also written Lampit.
- studies test it
- 10
- open now
- 0
- in phase 3
- 3
- first study started
- 2006
How studies write it
Studies that test it under each name
Brand
Studies by the year they started
9 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 3
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 5
Bayer (5) · Giselle Sholler (1) · University of Texas, El Paso (1) · Drugs for Neglected Diseases (1) · University of Vermont (1) · Universidad Autónoma de Bucaramanga (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Nifurtimox is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma CruziCompletedPhase 3BayerNCT02625974Written as Nifurtimox (Lampit, BAYA2502)
- Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or MedulloblastomaCompletedPhase 2Giselle ShollerNCT00601003Written as Nifurtimox
- New Therapies and Biomarkers for Chagas InfectionCompletedPhase 2University of Texas, El PasoNCT03981523Written as Nifurtimox
- Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits StudyCompletedPhase 1BayerNCT03334838Written as Nifurtimox (Lampit, BAYA2502)
- Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mgCompletedPhase 1BayerNCT03350295Written as Nifurtimox (Lampit, BAYA2502)
- CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)Status unknownPhase 2/3Universidad Autónoma de BucaramangaNCT02369978Written as Nifurtimox
- Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' PatientsCompletedPhase 1BayerNCT02606864Written as Nifurtimox (BAYa2502)
- Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African TrypanosomiasisCompletedPhase 3Drugs for Neglected DiseasesNCT00146627Written as Nifurtimox
- Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' PatientsCompletedPhase 1BayerNCT01927224Written as Nifurtimox (BAYa2502) (4 x 30 mg tablet)
- Safety Study of Nifurtimox for Relapsed or Refractory NeuroblastomaCompletedPhase 1University of VermontNCT00486564Written as Nifurtimox
As the comparator · 1 — what is tested is compared with Nifurtimox
Codes
What other systems call Nifurtimox · ClinicalTrials.gg INT007892
- MeSH (NLM) D009547NifurtimoxConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) M84I3K7C2ONIFURTIMOXConfirmed FDA, NLM, Wikidata
- RxNorm 7421Confirmed FDA, Wikidata
- Wikidata Q411582nifurtimoxConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71734NifurtimoxOne source FDA
- DrugBank DB11820One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D009547 | Nifurtimox | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | M84I3K7C2O | NIFURTIMOX | Confirmed FDA, NLM, Wikidata |
| RxNorm | 7421 | — | Confirmed FDA, Wikidata |
| Wikidata | Q411582 | nifurtimox | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71734 | Nifurtimox | One source FDA |
| DrugBank | DB11820 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.